Grubliauskaite Monika, Gudleviciene Zivile, Oskam Irma C, Asadi-Azarbaijani Babak, Jahnukainen Kirsi
Life Sciences Center, Vilnius University, Vilnius, Lithuania.
Department of Biobank, National Cancer Institute, Vilnius, Lithuania.
JCO Oncol Pract. 2025 Nov;21(11):1681-1688. doi: 10.1200/OP-24-00623. Epub 2025 Apr 4.
Despite new medicine and treatment options, fertility is impaired for many childhood cancer survivors after gonadotoxic treatment. In the current study, we compiled an overview on the state of fertility preservation (FP) care and limitations for childhood cancer patients throughout the Nordic-Baltic region.
In partnership with the Nordic Society of Pediatric Hematology and Oncology, an anonymous survey was conducted among 23 major pediatric oncology centers in Nordic and Baltic countries. The survey featured 22 multiple-choice and open-ended questions that provided insights into guidelines, available FP options, clinical indications, and counseling.
The response rate to the questionnaire was 74% (17 of 23 pediatric oncology centers). The survey revealed that only 65% of the centers have national guidelines on FP at the time. Although all centers offer counseling before treatment by oncologists (88%) or gynecologists (65%), 76% of the centers provide it only to those fulfill inclusion criteria. Additionally, counseling is unavailable for some patients because of age (35%), communication issues (29%), or lack of time (24%). Predominantly, sperm cryopreservation is offered across all centers for pubertal boys, while testicular tissue cryopreservation is provided at 41% of pediatric oncology centers for prepubertal boys. Oocyte cryopreservation is offered to pubertal girls at 88% of the centers, and ovarian tissue cryopreservation is offered to prepubertal and pubertal girls at 82% of the questioned centers.
The survey highlights the implementation of FP services status in the Nordic and Baltic countries. However, standardizing FP indications and disseminating guidelines widely is crucial to reduce clinical variability. Addressing issues such as inconsistent counseling, limited collaboration, and unclear risk stratification can drive further improvements.
尽管有了新的药物和治疗方案,但许多接受性腺毒性治疗的儿童癌症幸存者的生育能力仍受到损害。在当前的研究中,我们汇编了一份关于北欧 - 波罗的海地区儿童癌症患者生育力保存(FP)护理状况和局限性的概述。
与北欧儿科血液学和肿瘤学会合作,对北欧和波罗的海国家的23个主要儿科肿瘤中心进行了一项匿名调查。该调查包含22个多项选择题和开放式问题,这些问题提供了有关指南、可用的FP选项、临床适应症和咨询方面的见解。
问卷的回复率为74%(23个儿科肿瘤中心中的17个)。调查显示,当时只有65%的中心有关于FP的国家指南。尽管所有中心都在治疗前由肿瘤学家(88%)或妇科医生(65%)提供咨询,但76%的中心仅向符合纳入标准的患者提供咨询。此外,由于年龄(35%)、沟通问题(29%)或时间不足(24%),一些患者无法获得咨询。主要地,所有中心都为青春期男孩提供精子冷冻保存,而41%的儿科肿瘤中心为青春期前男孩提供睾丸组织冷冻保存。88%的中心为青春期女孩提供卵母细胞冷冻保存,82%的被调查中心为青春期前和青春期女孩提供卵巢组织冷冻保存。
该调查突出了北欧和波罗的海国家FP服务的实施现状。然而,规范FP适应症并广泛传播指南对于减少临床差异至关重要。解决诸如咨询不一致、合作有限和风险分层不明确等问题可以推动进一步的改进。